Microfluidic particle counter visualizing mucosal antibodies against SARS-CoV-2 in the upper respiratory tract for rapid evaluation of immune protection

• Published in: Lab on a chip 2024-05, Vol.24 (1), p.2658-2668
• Main Authors: Li, Jiaheng, Chu, Lok Ting, Hartanto, Hogi, Guo, Guihuan, Liu, Lu, Wu, Jianpeng, Wu, Minghui, Cui, Chenyu, Wang, Gaobo, Liu, Wengang, Kwong, Hoi Kwan, Wu, Siying, Chen, Ting-Hsuan
• Format: Article
• Language: English
• Subjects: Antibodies; Antibodies, Viral - analysis; Antibodies, Viral - immunology; COVID-19 - diagnosis; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; Humans; IgG antibody; Immunoglobulin G - blood; Immunoglobulin G - immunology; Lab-On-A-Chip Devices; Magnetic separation; Microfluidic Analytical Techniques - instrumentation; Microfluidics; Microparticles; Nasal Mucosa - immunology; Polystyrene resins; Radiation counters; SARS-CoV-2 - immunology; SARS-CoV-2 - isolation & purification; Secretions; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology
• ISSN: 1473-0197; 1473-0189; 1473-0189
• DOI: 10.1039/d4lc00118d

Mucosal antibodies in the upper respiratory tract are the earliest and most critical responders to prevent respiratory infections, providing an indication for the rapid evaluation of immune protection. Here, we report a microfluidic particle counter that directly visualizes mucosal antibody levels in nasal mucus. The mucosal anti-SARS-CoV-2 spike receptor binding domain (RBD) antibodies in nasal secretions first react with magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) that are surface-modified to form a "MMPs-anti-spike RBD IgG-PMPs" complex when RBD is present. After magnetic separation and loading into the microfluidic particle counter, the free PMPs, which are reduced with increasing anti-spike RBD IgG antibody levels, are trapped by a microfluidic particle dam and accumulate in the trapping channel. A sensitive mode [limit of detection (LOD): 14.0 ng mL −1 ; sample-to-answer time: 70 min] and an equipment-free rapid mode (LOD: 37.4 ng mL −1 ; sample-to-answer time: 20 min) were achieved. Eighty-seven nasal secretion (NS) samples from vaccinees were analyzed using our microfluidic particle counter, and the results closely resemble those of the gold-standard enzyme-linked immunosorbent assay (ELISA). The analysis shows that higher antibody levels were found in convalescent volunteers compared to noninfected volunteers. Together, we demonstrate a rapid kit that directly indicates immune status, which can guide vaccine strategy for individuals and the government. A microfluidic particle counter for visualizing mucosal antibody levels against SARS-CoV-2 in the upper respiratory tract for rapid evaluation of immune protection.